Teva — Pharmaceutical Intelligence | Humanexa Signals

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for Pomalidomide by Teva Pharmaceuticals

Teva Pharmaceuticals has submitted a supplemental application for Pomalidomide, which is currently under review by the FDA.

Recent signals(34)

Teva's Losartan Potassium Supplement Application Receives Standard Review Status

Teva's Gabapentin ANDA075435 Receives AP Status from FDA

Teva's Gabapentin ANDA205807 Receives AP Status from FDA

Upcoming catalysts

Regulatory activity(22)

Teva's Losartan Potassium Supplement Application Receives Standard Review Status

Teva's Sugammadex Sodium Receives FDA Approval Status

FDA Accepts Supplemental Application for Pomalidomide by Teva Pharmaceuticals

Clinical activity(3)

Teva initiates trial for TEV-56286 assessing pharmacokinetics and safety

Teva's TEV-56286 Trial for Multiple System Atrophy Underway

Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy

Competitive activity

Assets

Therapeutic areas

Indications

Get signals before the market moves

Teva's Sugammadex Sodium Receives FDA Approval Status

FDA Accepts Supplemental Application for Pomalidomide by Teva Pharmaceuticals

FDA Acceptance of Supplemental NDA for ZIAC by Teva

FDA Approves Supplemental NDA for ZIAC by Teva

FDA Submission Update for Canagliflozin by Teva Pharmaceuticals

FDA Accepts Application for Budesonide and Formoterol Fumarate Dihydrate

FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals

FDA Grants Approval for Teva's Tolvaptan ANDA216933

Teva's ANDA Submission for Canagliflozin Receives TA Status

FDA Approval Application for Linagliptin by Teva Pharmaceuticals

Teva's Eltrombopag Olamine ANDA209938 Receives Approval

Teva Pharmaceuticals Receives AP Status for Gabapentin Supplement

Teva's Gabapentin ANDA205807 Receives Approval Status from FDA

Teva's Finasteride ANDA076511 Receives Abbreviated Approval from FDA

Teva's Nilotinib Hydrochloride ANDA219134 Receives AP Status from FDA

FDA Accepts Supplemental Application for Copaxone (Glatiramer Acetate)

Teva Pharmaceuticals submits supplemental application for Pomalidomide

Teva initiates trial for TEV-56286 assessing pharmacokinetics and safety

Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval

Teva's Glycerol Phenylbutyrate ANDA218738 Receives AP Status from FDA

FDA Accepts Supplemental Application for Argatroban by Teva Pharmaceuticals

Teva's Argatroban Supplement Receives FDA Acceptance

FDA Approves Supplemental Application for AJOVY (Fremanezumab)

FDA Accepts Supplement Application for Teva's Morphine Sulfate

Teva's ANDA219324 for Junel FE Receives Approval Status from FDA

FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

FDA Approval Update for Teva's Tramadol Hydrochloride Supplement

FDA Grants AP Status for Teva's Risedronate Sodium Supplement

FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals

Teva's TEV-56286 Trial for Multiple System Atrophy Underway

Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy

FDA Acceptance of Supplemental NDA for ZIAC by Teva

FDA Approves Supplemental NDA for ZIAC by Teva

FDA Accepts Application for Budesonide and Formoterol Fumarate Dihydrate

FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals

Teva's Eltrombopag Olamine ANDA209938 Receives Approval

Teva Pharmaceuticals Receives AP Status for Gabapentin Supplement

Teva's Gabapentin ANDA205807 Receives Approval Status from FDA

Teva's Nilotinib Hydrochloride ANDA219134 Receives AP Status from FDA

FDA Accepts Supplemental Application for Copaxone (Glatiramer Acetate)

Teva Pharmaceuticals submits supplemental application for Pomalidomide

Teva's Glycerol Phenylbutyrate ANDA218738 Receives AP Status from FDA

FDA Accepts Supplemental Application for Argatroban by Teva Pharmaceuticals

Teva's Argatroban Supplement Receives FDA Acceptance

FDA Approves Supplemental Application for AJOVY (Fremanezumab)

FDA Accepts Supplement Application for Teva's Morphine Sulfate

Teva's ANDA219324 for Junel FE Receives Approval Status from FDA

FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

FDA Approval Update for Teva's Tramadol Hydrochloride Supplement

FDA Grants AP Status for Teva's Risedronate Sodium Supplement